| Trial ID: | L6749 |
| Source ID: | NCT00924105
|
| Associated Drug: |
Cyt013-Il1bqb
|
| Title: |
Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: CYT013-IL1bQb|DRUG: Placebo
|
| Outcome Measures: |
Primary: Incidence of adverse events, continously | Secondary: Biological measures of glycemia and inflammation, continously
|
| Sponsor/Collaborators: |
Sponsor: Cytos Biotechnology AG
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
48
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-06
|
| Completion Date: |
2011-11
|
| Results First Posted: |
|
| Last Update Posted: |
2012-02-13
|
| Locations: |
Cytos Investigator sites, Hamburg, Germany|Cytos Investigator sites, Basel, Switzerland|Cytos Investigator sites, Zuerich, Switzerland
|
| URL: |
https://clinicaltrials.gov/show/NCT00924105
|
